The Tumor Procurement and Pathology Core will provide: (i) Tumor and matched normal control tissue, (ii) Pathology review and classification, (iii) Anonymized clinical and outcome data, (iv) Purified RNA and DNA, (v) Tissue arrays. This Core will be responsible for appropriate procurement, processing and storage of clinical tissue, selecting sufficient and appropriate samples for meaningful clinical correlations, prioritizing and distributing tissue to maximize utility, and providing expertise in histopathology, molecular pathology and tissue-based experimentation. Further, the Core will accurately collect and organize clinical and pathologic data, provide clinical data management and provide efficient data, query, access and transfer for correlative analyses. The overall objective of this core is to provide an efficient high quality, centralized pathology and clinical research resource supporting the projects in this program.
The specific aims of this core facility are to: (i) Provide pathology, clinical and database management expertise at all stages of project development and experimentation using human tissue. (ii) Procure well-characterized neoplastic and non-neoplastic human tissue required for individual projects without compromise of patient care. (iii) Record and maintain pertinent clinical and histopathology data in a secure, anonymized relational database designed for efficient data transfer and analyses of genetic, epigenetic, and molecular correlations in Projects 1, 2, and 3. (iv) Process, store, and distribute tissue samples and biomaterials according to the needs of investigators in Projects 1 and 2.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA065930-05A2
Application #
6683037
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-08-30
Project End
2006-06-30
Budget Start
Budget End
Support Year
5
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Type
DUNS #
201373169
City
New York
State
NY
Country
United States
Zip Code
10065
Khan, Sajid A; Zeng, Zhaoshi; Shia, Jinru et al. (2017) EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathol Oncol Res 23:673-677
Khan, Sajid A; Morris, Melinda; Idrees, Kamran et al. (2016) Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. J Pediatr Surg 51:1812-1817
Cheng, Yu-Wei; Pincas, Hanna; Huang, Jianmin et al. (2014) High incidence of LRAT promoter hypermethylation in colorectal cancer correlates with tumor stage. Med Oncol 31:254
Bacolod, Manny D; Barany, Francis (2011) Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol 18:3694-700
Dharmasiri, Udara; Njoroge, Samuel K; Witek, Ma?gorzata A et al. (2011) High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Anal Chem 83:2301-9
Pingle, Maneesh; Rundell, Mark; Das, Sanchita et al. (2010) PCR/LDR/universal array platforms for the diagnosis of infectious disease. Methods Mol Biol 632:141-57
Nash, Garrett M; Gimbel, Mark; Shia, Jinru et al. (2010) KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 17:572-8
Nash, Garrett M; Gimbel, Mark; Cohen, Alfred M et al. (2010) KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol 17:416-24
Bacolod, Manny D; Barany, Francis (2010) Gene dysregulations driven by somatic copy number aberrations-biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 12:552-61
Cheng, Yu-Wei; Idrees, Kamran; Shattock, Richard et al. (2010) Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer. Int J Cancer 127:568-77

Showing the most recent 10 out of 74 publications